A study has shed new light on the mechanisms behind idiopathic inflammatory myopathies (myositis), a group of systemic autoimmune disorders known for causing severe muscle weakness, fatigue, and ...

Pain is common among patients with IIMs and is linked to worse physical function, increased fatigue, and reduced quality of life.

Myositis, a relatively uncommon autoimmune disorder, develops because of abnormal activation of the body's immune cells against muscles. Inflammatory myopathies involve four major subtypes that ...

Here are the types, symptoms, causes, treatments, and outlook for myositis and where to find support.

Idiopathic Inflammatory Myopathies (IIMs): Let us understand idiopathic inflammatory myopathies through myositis antibodies.

Myositis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Roche, Pfizer, Zydus Group, Lupin, Bausch Health, Accord Healthcare ...

Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIAPotential for ...

Inflammatory myopathies are inflammatory infiltrates in the muscle. This group of diseases includes polymyositis, dermatomyositis, and inclusion-body myositis. Little is known about the cause and ...

Recent findings regarding interferon and Janus kinase inhibition may hold clues to improving outcomes in patients with complex myositis, according to a presenter at the Biologic Therapies Summit ...

The ALKIVIA study is a randomized, double-blind, placebo-controlled, multicenter, operationally seamless Phase 2/3 study of efgartigimod SC for the treatment of idiopathic inflammatory myopathies (IIM ...